General
Preferred name
DIMETHYL FUMARATE
Synonyms
DMF ()
Tecfidera ()
DMF,Tecfidera,BG-12 ()
Fumaric acid dimethyl ester ()
FP187 ()
BG 12 ()
AZL 0 211089 ()
AZL-O-211089 ()
FP-187 ()
AZL-0211089 ()
Las41008 ()
BG-00012 ()
BG-12 ()
NSC-167432 ()
FAG-201 ()
Panaclar ()
BG00012 ()
NSC-25942 ()
BG 00012 ()
Dimethyl fumar ()
LAS-41008 ()
AZL O 211089 ()
P&D ID
PD000183
CAS
624-49-7
624-48-6
23055-10-9
12287-98-8
Tags
covalent binder
prodrug
natural product
drug
available
Approved by
EMA
FDA
First approval
2013
Drug Status
investigational
approved
Drug indication
Multiple sclerosis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The active metabolite of dimethyl fumarate is . (GtoPdb)
HALF-LIFE MMF has a short half life of about 1 hour, and MMF does not accumulate after repeated doses of dimethyl fumarate.;
METABOLISM Dimethly fumarate is hydrozlied to its metabolite MMF in the GIT, tissues, and blood by esterases. MMF then undergoes subsequent metabolism in the tricarboxylic acid (TCA) cycle. Altogether the main metabolites formed are MMF, glucose, citric acid, and fumaric.; ;
ROE The main route of elimination is by CO2 exhalation that accounts for 60% of the dose. The other minor routes are through the kidney (16% metabolites and trace amounts of unchanged MMF) and the feces (1%).; ;
ABSORPTION Once ingested, dimethyl fumarate is rapidly hydroylyzed by esterases to MMF. Thus there is negligible amount of dimethyl fumarate in the body, and all pharmacokinetic information is quantified with MMF. In multiple sclerosis patients, the time to maximum concentration of MMF is 2 to 2.5 hours and the maximum concentration is 1.87 mg/L. ;
DESCRIPTION Na+/Ca2+ exchange inhibitor (reverse mode); neuroprotective (Tocris Bioactive Compound Library)
Compound Sets
20
Cayman Chemical Bioactives
14714
ChEMBL Approved Drugs
CHEMBL2107333
ChEMBL Drugs
CHEMBL2107333
CovalentInDB
CI003189
Drug Repurposing Hub
DrugBank
DB08908
DrugBank Approved Drugs
DB08908
DrugCentral
4757
DrugCentral Approved Drugs
4757
DrugMAP
DM2OVDT
DrugMAP Approved Drugs
DM2OVDT
Enamine BioReference Compounds
Guide to Pharmacology
7045
MedChem Express Bioactive Compound Library
HY-17363
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
dimethyl-Fumarate
TargetMol Bioactive Compound Library
T0492
The Spectrum Collection
Tocris Bioactive Compound Library
4512
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
144.04
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
0
Aromatic Ring Count
0
cLogP
-0.11
TPSA
52.6
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
0.0
QED
0.4
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
NF-¦ÊB
NF-??
Anti-infection
Autophagy
Immunology/Inflammation
Metabolic Enzyme/Protease
NF-κB
Target
Keap1-Nrf2
KEAP1
Endogenous Metabolite
HIV
Reactive Oxygen Species
Nrf2
Primary Target
Antioxidants
Member status
member
MOA
Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators
NF-kappaB (NFKB) Activation Inhibitors
Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands
nuclear factor erythroid derived, like (NRF2) activator
Indication
multiple sclerosis
Source data